AMILI is Southeast Asia’s first and only precision gut microbiome company serving as a hub for gut microbiome innovation and therapy. Our aim is to advance microbiome research, grounded in science and compassion, to address unmet and critical needs in healthcare with the potential to positively impact millions of lives across Asia. 

United by a shared belief that science can be a powerful driver for the greater good when combined with ethically- and scientifically-backed tools, our cross-disciplinary team is creating a sustainable platform for the collection, processing and distribution of gut microbiome-derived products to hospitals and research institutions.  

We are also building the world’s largest multi-ethnic, Asia-centric gut microbiome database to support fundamental discovery into the impact of the gut microbiome on human health in Asia.  

As a Singapore-based healthcare organization, we not only leverage the infrastructure and resources of one of Asia’s top biomedical hubs, but also have access to the city’s diverse and global populations to help further purpose-driven science.